跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AG-DAPAGLIFLOZIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AG-DAPAGLIFLOZIN
Authorized
STANDARD
AG-DAPAGLIFLOZIN
angita pharma inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ec78a54c38be29d9
Company
angita pharma inc.
Type
Standard
Approval Details
Approval Id
ec78a54c38be29d9
Drug Approval Canada Name
AG-DAPAGLIFLOZIN
Product Name
AG-DAPAGLIFLOZIN
Status
Marketed
Status Date
2023-05-15
Original Market Date
2023-05-15
Din
02533049
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.18
Atc Original
A10BK01 DAPAGLIFLOZIN
Atc Name
a 10 bk 01
Aig Number
0156370001
Company Name
angita pharma inc.
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Active Ingredients
DAPAGLIFLOZIN
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ec78a54c38be29d9
Type
Standard
Back to Health Canada Approvals